NewAge, Inc. Announces Third Quarter 2021 Financial Results With Revenue Growth of 59%
DENVER, Nov. 09, 2021 (GLOBE NEWSWIRE) -- NewAge, Inc. (Nasdaq: NBEV), the Colorado-based direct-to-consumer (D2C) organic and healthy products company, today announced financial results for the third quarter of 2021.
|Third Quarter 2021 Highlights|
|-||Net revenue increased 59% to $100 million compared to $63 million in the third quarter of 2020|
|-||Gross profit was $66 million compared to $37 million in the prior year third quarter, an increase of $29 million|
|-||Gross margin reached 66.3% of net revenue compared to 59.8% of revenue in the prior year third quarter, up 6.5 points|
|-||Net income improved $11.4 million to ($2.7) million, or ($0.02) per basic share|
|-||Adjusted EBITDA1 improved $4.0 million to ($4.4) million versus ($8.4) million in the prior year third quarter|
Brent Willis, Chief Executive Officer of NewAge, commented, “We continue to build NewAge into a leading social selling machine, and I am encouraged by the operational progress we made during the quarter, setting us up well for the rest of the year and beyond. This quarter we made investments in our systems, launched new products, and unveiled new social selling tools and technology, all of which are critical foundational components and will act as a springboard for growth. Our results in the third quarter for revenue, gross margin, net income and adjusted EBITDA all improved year over year, and we expect our future results to benefit substantially from all the actions we have taken in the quarter and earlier in the year.
“Our healthy products portfolio is on trend and we continue to strengthen our offerings and our systems around the world, supported by a robust supply chain. Our inventory levels and our D2C route to market help to alleviate many of the supply chain concerns plaguing the wider consumer goods market. We have a lot of confidence in our direct-to-consumer and social selling business model, and are excited as our proposition and financial results begin to unfold,” concluded Mr. Willis.
Third Quarter 2021 Financial Results
Net revenue was $100 million for the three months ending September 30, 2021, versus $63 million for the third quarter of the prior year, an increase of 59%. The year-over-year growth in net revenue was driven by the acquisitions of ARIIX and Aliven. Sequentially, net revenue decreased versus the previous quarter, due in part to the impact of COVID-19 in a number of markets around the world, and a planned systems consolidation which caused disruptions in the selling cycle.
Gross profit for the third quarter of 2021 was $66 million, or 66.3% of net revenue, compared with $37 million, or 59.8% of net revenue, for the prior-year period, representing a 76% increase of $29 million and an increase of 6.5 gross margin percentage points. The gross margin percentage increase was driven by a higher mix of net revenue from the Direct/Social Selling segment, which has a higher margin than the Direct Store segment.
Selling, general and administrative (SG&A) expense for the third quarter totaled $39 million, or 39.2% of revenue, compared to $28 million, or 44.6% of revenue, for the prior-year period. The year-over-year improvement in SG&A expense as a percentage of net revenue primarily reflects the benefits of a growing business and elimination of redundant positions and offices.
Operating loss was $30.4 million for the third quarter of 2021 compared to a loss of $13.1 million for the prior-year period. Net loss was $2.7 million, or $0.02 per basic share, compared to a net loss of $14.1 million, or $0.14 per basic share, in the prior-year period. Adjusted EBITDA improved $4.0 million to a loss of $4.4 million, compared to a loss of $8.4 million in the prior-year period.
Balance Sheet and Liquidity
The Company ended the quarter with a strong balance sheet, with total cash and cash equivalents of $62.3 million and debt of $17.6 million, exclusive of operating lease liabilities.
Conference Call Information
A conference call and audio webcast with analysts and investors will be held today at 5:00 p.m. Eastern Time/3:00 p.m. Mountain Time to discuss the results and answer questions.
- Live conference call: 1-800-926-9801 (domestic) or 1-303-223-0113 (international) with conference ID: 21998666.
- Conference call replay available through November 16, 2021: 1-844-512-2921 (domestic) or 1-412-317-6671 (international) with replay access code: 21998666.
- Live and archived webcast will be available on the Conference Calls page of NewAge’s investor relations website at https://newage.com/investors.
1EBITDA and Adjusted EBITDA are non-GAAP financial measures with reconciliations provided in the accompanying financial tables.
About NewAge, Inc.
NewAge is a purpose-driven firm dedicated to inspiring the planet to Live Healthy™. Colorado-based NewAge commercializes a portfolio of organic and healthy products worldwide through primarily a direct-to-consumer (D2C) route to market distribution system across more than 50 countries. The company competes in three major category platforms including health and wellness, inner and outer beauty, and nutritional performance and weight management — through a network of exclusive independent Brand Partners, empowered with the leading social selling tools and technology available worldwide. More information on the Company can be found at NewAge.com.
Forward Looking Statements
This press release contains forward-looking statements that are made under the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management's expectations regarding future results of operations, economic performance, and financial condition, including statements related to operating margins, the acquisitions and integrations of ARIIX and Aliven and cost synergies and operational efficiencies related thereto, the acquisition of additional businesses, the impact of the coronavirus (“COVID-19”) pandemic, and plans for company growth. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. NewAge competes in a rapidly growing and transforming industry, and risk factors, including those disclosed in the company's filings with the Securities and Exchange Commission, might affect the company's operations. Unless required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements.
Non-GAAP Financial Measures
The primary purpose of using non-GAAP financial measures is to provide supplemental information that we believe may be useful to investors and to enable investors to evaluate our results in the same way we do. We also present non-GAAP financial measures because we believe they assist investors in comparing our performance across reporting periods on a consistent basis, as well as comparing our results against the results of other companies, by excluding items that we do not believe are indicative of our core operating performance. Specifically, we use these non-GAAP measures as measures of operating performance; to prepare our annual operating budget; to allocate resources to enhance the financial performance of our business; to evaluate the effectiveness of our business strategies; to provide consistency and comparability with past financial performance; to facilitate a comparison of our results with those of other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results; and in communications with our board of directors concerning our financial performance. Investors should be aware, however, that not all companies define these non-GAAP measures consistently.
EBITDA is defined as net income (loss) adjusted to exclude amounts recorded under GAAP for interest expense, income tax expense, and depreciation and amortization expense. For the calculation of Adjusted EBITDA, we also exclude the following items for the periods presented:
Loss (gain) from change in fair value of derivatives: We have excluded derivative gains and losses since they can be highly volatile from period to period based on factors that are outside the control of our core business activities. Specifically, the variations that impact fair value heavily depend on the trading price of our Common Stock and global interest rates. As a result, gains and losses from changes in the fair value of derivatives vary for reasons that are generally unrelated to operational decisions and performance in any particular period.
Gain from forgiveness of PPP Loans and accrued interest: We have excluded the gain from forgiveness of PPP Loans and accrued interest due to the unique terms of this U.S. governmental assistance which is unrelated to operational performance.
Impairment of long-lived assets: We have excluded charges for impairment of long-lived assets that were primarily triggered by an amendment to our business combination agreement that is unrelated to ongoing operational decisions and performance.
Stock-based compensation expense: Our compensation strategy includes the use of stock-based compensation to attract and retain employees, directors and consultants. This strategy is principally aimed at aligning the employee interests with those of our shareholders and to achieve long-term employee retention, rather than to motivate or reward operational performance for any particular period. As a result, stock-based compensation expense varies for reasons that are generally unrelated to operational decisions and performance in any particular period.
Employee severance and office closure expenses: We have excluded charges for employee severance and office closure expenses that are typically incurred to enable us to realize synergies in merger and divestiture transactions, and to execute our other strategies designed to improve performance.
Loss on disposal of Divested Business: We have excluded losses related to our disposal of the Divested Business since those losses are unrelated to current operational decisions and performance.
VP, Investor Relations
|UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS|
|(In thousands, except per share amounts)|
|September 30,||December 31,|
|Cash and cash equivalents||$||46,829||$||43,711|
|Trade accounts receivable, net of allowance of $918 and $582, respectively||8,873||12,341|
|Prepaid expenses and other||15,123||13,032|
|Current portion of restricted cash||12,000||10,000|
|Assets held for sale||6,884||-|
|Total current assets||138,585||127,135|
|Identifiable intangible assets, net of accumulated amortization||144,539||169,611|
|Right-of-use lease assets||29,580||38,764|
|Property and equipment, net of accumulated depreciation||22,786||28,076|
|Deferred income taxes||7,404||7,782|
|Deposits and other||4,621||5,297|
|Restricted cash, net of current portion||3,514||11,524|
|LIABILITIES, REDEEMABLE COMMON STOCK, AND STOCKHOLDERS’ EQUITY|
|Current maturities of long-term debt||17,636||18,016|
|Operating lease liability related to right-of-use assets held for sale||4,503||-|
|Current portion of business combination liabilities||1,140||11,750|
|Total current liabilities||97,809||122,547|
|Business combination liabilities, net of current portion||28,222||95,826|
|Long-term debt, net of current maturities||-||16,181|
|Operating lease liabilities, net of current portion:|
|Deferred lease financing obligation||15,372||15,882|
|Deferred income taxes||5,019||5,391|
|Warrant derivative liability||1,782||-|
|Redeemable Common Stock, 800 shares as of December 31, 2020||-||2,101|
|Preferred stock, $0.001 par value per share. Authorized 1,000 shares; no shares issued||-||-|
|Common Stock, $0.001 par value per share. Authorized 400,000 and 200,000 shares as|
|of September 30, 2021 and December 31, 2020, respectively; issued and outstanding 146,816 and||147||99|
|99,146 shares as of September 30, 2021 and December 31, 2020, respectively|
|Additional paid-in capital||363,205||236,732|
|Obligation to issue 4,551 and 19,704 shares of Common Stock as of September 30, 2021|
|and December 31, 2020, respectively||9,464||54,186|
|Note receivable for stock subscription||-||(1,250||)|
|Accumulated other comprehensive income||4,204||4,201|
|Total stockholders' equity||222,108||142,153|
|Total liabilities, redeemable Common Stock, and stockholders' equity||$||405,650||$||443,182|
|UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In thousands, except per share amounts)|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Cost of goods sold||33,567||25,224||111,925||71,952|
|Selling, general and administrative||39,027||27,983||118,928||84,868|
|Impairment of long-lived assets||16,186||-||16,186||400|
|Depreciation and amortization expense||4,385||1,751||13,783||5,293|
|Loss on disposal of Divested Business||-||3,446||4,339||3,446|
|Total operating expenses||96,421||50,638||280,776||149,385|
|Non-operating income (expense):|
|Gain (loss) from change in fair value of derivatives||19,498||(86||)||40,714||(392||)|
|Gain from forgiveness of PPP Loans and accrued interest||9,751||-||9,751||-|
|Interest and other income, net||1,397||229||992||954|
|Loss before income taxes||(2,315||)||(13,521||)||(822||)||(33,419||)|
|Income tax expense||(385||)||(612||)||(2,275||)||(1,886||)|
|Net loss per share of Common Stock:|
|Weighted average number of shares of Common Stock outstanding:|
|UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|NINE MONTHS ENDED SEPTEMBER 2021 AND 2020|
|CASH FLOWS FROM OPERATING ACTIVITIES:|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Loss (gain) from change in fair value of derivatives, net||(40,714||)||392|
|Gain from forgiveness of PPP Loans and accrued interest||(9,751||)||-|
|Impairment of long-lived assets||16,186||400|
|Depreciation and amortization||14,077||5,607|
|Non-cash lease expense||7,381||3,913|
|Accretion of debt discount||6,171||414|
|Stock-based compensation expense||5,624||3,415|
|Allowance for uncollectible note receivable and accrued interest from Divested Business||2,701||-|
|Deferred income tax expense (benefit)||490||(442||)|
|Loss from sale of property and equipment||332||128|
|Loss on disposal of Divested Business||-||3,446|
|Changes in operating assets and liabilities, net of effects of business combination:|
|Trade accounts receivable||240||(932||)|
|Prepaid expenses, deposits and other||117||519|
|Other accrued liabilities||(20,486||)||(13,738||)|
|Net cash used in operating activities||(25,613||)||(29,853||)|
|CASH FLOWS FROM INVESTING ACTIVITIES:|
|Cash payments for Ariix business combination||(10,000||)||-|
|Capital expenditures for property and equipment||(1,267||)||(2,108||)|
|Cash advance under unsecured promissory note||-||(1,250||)|
|Proceeds from sale of equipment||4||231|
|Proceeds received from buyer of Divested Businesses, net of cash conveyed of $209||-||381|
|Net cash used in investing activities||(11,263||)||(2,746||)|
|CASH FLOWS FROM FINANCING ACTIVITIES:|
|Proceeds from private placement of Units, net of placement fee:|
|Fair value of warrants to purchase 7,318 shares of Common Stock||14,128||-|
|Residual fair value of 14,636 shares of Common Stock||39,673||-|
|Proceeds from exercise of stock options||530||34|
|Proceeds from issuance of common stock||-||25,122|
|Proceeds from borrowings||-||6,868|
|Principal payments on borrowings||(12,000||)||(10,825||)|
|Principal payments on business combination obligations||(9,702||)||(5,761||)|
|Payments under deferred lease financing obligation||(495||)||(480||)|
|Debt issuance costs paid||(21||)||(95||)|
|Payments for deferred offering costs||(24||)||(164||)|
|Purchase and retirement of 780 shares of Common Stock||-||(1,193||)|
|Net cash provided by financing activities||32,089||13,506|
|Effect of foreign currency translation changes||1,895||(247||)|
|Net change in cash, cash equivalents and restricted cash||(2,892||)||(19,340||)|
|Cash, cash equivalents and restricted cash at beginning of period||65,235||64,571|
|Cash, cash equivalents and restricted cash at end of period||$||62,343||$||45,231|
|ADJUSTED EBITDA CALCULATION|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|EBITDA Non-GAAP adjustments:|
|Income tax expense||385||612||2,275||1,886|
|Depreciation and amortization expense||4,481||1,855||14,077||5,607|
|Adjusted EBITDA Non-GAAP adjustments:|
|Loss (gain) from change in fair value of derivatives||(19,498||)||86||(40,714||)||392|
|Gain from forgiveness of PPP Loans and accrued interest||(9,751||)||-||(9,751||)||-|
|Impairment of long-lived assets||16,186||-||16,186||400|
|Employee severance and office closure expenses||2,520||1,658||4,217||2,543|
|Stock-based compensation expense||1,475||966||5,624||3,415|
|Loss on disposal of Divested Business||-||-||4,339||3,446|